Professor Li walked into the café with the latest issue of The Lancet magazine. He invited a few colleagues to chat and talk about recent research progress. He found a corner spot and sat down and waited for the others to arrive.

Less than five minutes after sitting down, Dr. Wang and Dr. Zhang also walked in. They are all old friends of Professor Li and well-known medical experts in China. When they saw Professor Li, they said hello briefly and sat down across from him.

"This is the latest issue of The Lancet, what's new?" Dr. Wang asked.

"I saw an interesting article about CRISPR gene-editing drugs for the treatment of advanced lung cancer, which is very interesting." Dr. Wang said.

"Oh? Gene Editing Drugs? Where is the research going? Which company's project? Dr. Zhang asked curiously.

"It's not bad, you can see for yourself." Professor Li directly handed over the Lancet magazine in his hand.

Dr. Zhang took it and looked at it directly, and Dr. Wang on the side also leaned his head and followed suit.

"A customized lung cancer drug based on CRISPR gene editing technology has shown significant anti-cancer effects in animal experiments. This drug can precisely repair or eliminate mutations or abnormal genes in cancer cells according to the tumor gene characteristics of each patient, so as to achieve the purpose of killing cancer cells or preventing their proliferation and metastasis.

Animal experiments on mice and rats have been completed, and human clinical trials are being applied.

In animal experiments, the drug was compared with conventional chemotherapy drugs. The results showed that the drug was able to significantly reduce the volume of lung cancer cell xenografts and prolong the survival time of animals.

In the mouse experiment, after 4 weeks of treatment, the average tumor volume was 50.6 cubic millimeters in the drug group, compared to 179.4 cubic millimeters in the chemotherapy group and 248.7 cubic millimeters in the control group. There were statistically significant differences between the drug group and the chemotherapy group and the control group (P<0.01).

In rat experiments, after 8 weeks of treatment, the average tumor volume was 68.3 cubic millimeters in the drug group, compared to 302.5 cubic millimeters in the chemotherapy group and 412.6 cubic millimeters in the control group. There were statistically significant differences between the drug group and the chemotherapy group and the control group (P<0.01).

In addition, in mouse experiments, the average survival time was 72 days in the drug group, compared to 48 days in the chemotherapy group and 38 days in the control group."

Dr. Zhang and Dr. Wang looked up after reading it, but they noticed the company name at the end.

“Aiying Biological Company？ Why do I look at this name, it feels a bit like the Aiying creature in our country. Dr. Zhang subconsciously muttered.

Dr. Wang also nodded in agreement, because during this time, when he was in his spare time, he could often see some news videos from self-media channels to push him the latest research results of Aiying Biotech.

So when I saw this name at this moment, the first thing that came to mind was the name of this domestic company.

"Well, yes. That's why I'm here for you. Professor Li nodded.

"Oh? What do you mean? After Dr. Wang finished speaking, he looked at Professor Li.

Dr. Zhang asked with a smile. "It seems that you have nothing to do but go to the Three Treasures Palace, I said, why did you, a busy person, suddenly invite a guest to dinner."

"This project is done by our domestic Aiying Biotech, and the project leader is my college classmate" Professor Li did not hide it, he said all the 1510, and directly took out two relevant details and handed them directly to the two.

The main reason for choosing these two friends is that they are the top doctors in related fields in China.

Although he is not a director or anything, he already has the title of deputy director, and he is still in the Cancer Hospital of the Medical Academy of Medical Sciences, the top hospital in China such as Xiehe, there is no shortage of medical ethics, medical skills, and patients.

Dr. Wang and Dr. Zhang are also distracted at the moment to study the specific details, and this drug is simply a customized drug.

"In the first step, a tumor tissue sample is removed from the patient's body and whole-exome sequencing and HLA typing are performed to determine the patient's TSA and its corresponding HLA restriction peptides.

In the second step, the corresponding gRNA is synthesized according to the patient's TSA and its HLA restriction peptide design, and binds to the Cas9 protein to form RNP complexes.

In the third step, peripheral blood mononuclear cells (PBMCs) were collected from the patient and CD8+ T lymphocytes were isolated.

In the fourth step, the RNP complex was transfected into CD8+ T lymphocytes, and the TSA-HLA restriction peptide coding sequence was inserted into the TCRα chain constant region gene by using the CRISPR-Cas9 system, so that CD8+ T lymphocytes could express specific TCRs and be able to recognize and kill tumor cells expressing the same TSA-HLA restriction peptide.

Finally, the edited and expanded CD8+ T lymphocytes were given back to the patient as an individualized CRISPR-Cas9 gene-edited immunotherapy. ”

"This kind of personalized plan is really good, but it is expensive," Dr. Wang couldn't help but joke.

When choosing which drug clinical trials to participate in, top doctors do not make decisions based on a combination of factors.

In general, doctors will cooperate with well-known pharmaceutical companies or institutions because of their own personal wishes, or the influence of the hospital's index policies, or personal career development.

"The innovation is good, there is also a good potential value, and the social demand is also very large, the only problem may be that the strength of pharmaceutical companies is average." Dr. Zhang also commented after reading it at this time.

"What the specific pricing is, this will have to wait until after the listing, and it is not clear now. But I think it will definitely be a lot cheaper than foreign ones. As for the strength of Aiying Biotech, if you only consider the time of establishment and the drugs that have been marketed, Aiying Biotech is even inferior to small factories in some places, but small factories are not willing to spend money to invest in multiple projects at the same time and invest large amounts of R&D expenses. Professor Li patiently explained.

"Lao Li, it seems that your classmates have told you inside information? Let's talk about it, let's get to know each other. Both Dr. Wang and Dr. Zhang looked at Professor Li.

"Well, I told you some, but I stated it in advance, and what I said next is just a retelling."

"When the boss of Aiying Biotech, that is, the young man Wu Zhou, recruited my classmate, one of the conditions given was that the annual R&D cost support should not be less than 100 million, and the second condition was that there was no limit to research, and the only requirement was that the research project must be a breakthrough in innovative product research."

"Last weekend, I had a conversation with my classmate about work, and according to him, Aiying Biotech exceeded its promise to him, and he did not hesitate to praise him and said that Aiying Biotech is the best scientific research institution he has ever stayed in, and there is no one."

In addition, as far as he knows, Aiying Biotech is currently researching in many fields, covering innovative drugs and biologics for major medical needs such as mask virus, cancer, cardiovascular, nervous system, etc., in addition to the application of cutting-edge technologies such as gene therapy and mRNA therapy, many of which are breakthrough innovative products. I think there will definitely be more and more related clinical projects in the future. Professor Li said with a smile, when talking about these cutting-edge people's scientific research projects.

Dr. Wang and Dr. Zhang also have slightly dilated pupils in their eyes, which sounds a little unreal.

"What stage have they reached in this clinical project?" Dr. Wang concluded that the process of a clinical project can be roughly divided into the following stages: pre-project initiation, project initiation, ethics review, genetic office review, contract signing, center initiation, clinical observation and trial completion, and it may take 3 to 6 months from project initiation to initiation.

"The project has just been established, but my classmate said that in the later clinical process of this project, if the effect is good, each cooperative doctor can make his own decision and increase the number of clinical recruitment places. After the later stage of the drug is launched, about 100 places will be given to charity every year."

"Hey, it's not bad money." Dr. Zhang, Dr. Wang, gasped at the same time.

(End of chapter)